Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dusquetide · 1 trial · 1 indication
The number of oral ulcers were counted at baseline and each visit during the treatment period.
The number of genital ulcers will be counted at baseline and each visit during the treatment period.
| Arm | Type | Description |
|---|---|---|
| SGX945 | EXPERIMENTAL | This is an open-label study and all participants will receive SGX945. |
| Name | Type | Description |
|---|---|---|
| Dusquetide | DRUG | 1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks |
Inclusion Criteria: * Participants must have a clinical diagnosis of Behcet's Disease meeting the International Study Group criteria. * Participants must have at least two oral ulcers and/or one genital ulcer on the day of randomization. * Participants willing to follow the clinical protocol and vo...
Top 20 of 24 competitors
Dusquetide is an investigational small molecule being studied for the treatment of Behçet Disease, a chronic inflammatory condition. It is currently in Phase 2 clinical development. The drug has been evaluated in a completed clinical trial involving 8 adult participants in Turkey.
Dusquetide is being developed by Soligenix, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol SNGX. The company is conducting clinical research on the drug for the treatment of Behçet Disease.
Dusquetide is in Phase 2 clinical development. It has completed a Phase 2 clinical trial for the treatment of Behçet Disease. The drug is investigational and has not been approved by regulatory authorities.
Dusquetide has been studied in one completed clinical trial with the identifier NCT06386744, titled "Dusquetide for the Treatment of Behcet's Disease." This Phase 2 trial enrolled 8 participants with Behçet Disease in Turkey and included adults aged 18 years and older.
Dusquetide is a distinct investigational small molecule developed by Soligenix, Inc. It is being studied specifically for the treatment of Behçet Disease and is not known to be identical to any other approved or investigational drug.